Impedimed is a medical device company that produces equipment capable of measuring changes in fluid levels in the human body in a highly accurate, non-invasive way. It has been given a Category 1 reimbursement code in the USA – the only other Australian listed... read more
The most important strategy we use to protect our investors’ capital is “setting a really high hurdle” on the investments we make. “We are looking for ’slam-dunk’ investments.” While having these high standards may result in missed opportunities, it gives the... read more
Emerchants’ has stable banking relationships with it’s UK & European banks that should be unaffected by the political uncertainty in the UK. Instead, we sees their expansion into the UK markets as an underappreciated opportunity. Based purely on the Australian... read more
Catapult recently acquired US-based sports video analytics company XOS Technologies for $US60 million ($80.1 million). The acquisition offers significant strategic value as it allows Catapult to leverage XOS’s sales team, who already have “very deep relationships”... read more
In this short video, see Simon in a panel discussion about IPO’s and what to look out for. As with any investment you need to do your homework to understand the business and form a view of its investment potential. Some of the key things to look out for... read more
The following information is only available to Sophisticated or Wholesale Investors. By submitting your details you are confirming that you are a Wholesale Investor as defined by the Australian Corporations Act.
Once you have submitted the form you will be able to download the PDS